20-F: Nyxoah SA Files 20-F Report: Details Financial Performance and Strategic Initiatives for 2024

Nyxoah SA's 20-F filing reveals the company's financial results for 2024, highlighting its focus on the Genio system and strategic expansion efforts.

Summary

• Nyxoah SA's 20-F filing details the company's financial performance and strategic initiatives for the year ended December 31, 2024.
• The company is focused on developing and commercializing the Genio system for obstructive sleep apnea (OSA) treatment.
• Nyxoah generated revenue of 4.5 million in 2024, compared to 4.3 million in 2023.
• The company incurred operating losses of 58.8 million in 2024 and 45.1 million in 2023.
• Nyxoah expects operating expenses to increase as it continues to develop its technology, expand manufacturing and sales capabilities, and seek regulatory approvals.
• The company expects to fund its operations for at least 12 months from the date of the report, based on current cash and cash equivalents of 34.2 million and financial assets of 51.4 million as of December 31, 2024.
• Nyxoah is pursuing marketing authorization for the Genio system in the United States and completed the primary data analysis from its DREAM trial.
• The company is also conducting additional clinical trials to expand the indications for the Genio system.
• Nyxoah is subject to extensive government regulation and oversight in the United States and abroad.
• The company identified material weaknesses in its internal control over financial reporting in connection with the audit of its 2024 financial statements.
• Nyxoah is taking remedial actions to address these material weaknesses.
• The company is exposed to various market risks, including foreign currency exchange rates and interest rates.
• Nyxoah is also subject to healthcare fraud and abuse laws and other laws applicable to its business activities.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is revenue growth, there are also significant operating losses and material weaknesses in internal control. The company is taking steps to address these issues, but there is still uncertainty about the future.

Positives

• Revenue increased to 4.5 million in 2024 from 4.3 million in 2023.
• The DREAM pivotal trial met its primary endpoints.
• The company is taking remedial actions to address material weaknesses in internal control over financial reporting.

Negatives

• Operating losses were 58.8 million in 2024 and 45.1 million in 2023.
• The company identified material weaknesses in its internal control over financial reporting in connection with the audit of its 2024 financial statements.

Risks

• The company may need to raise additional capital in the future, which may not be available on commercially favorable terms, or at all.
• The Genio system is still unapproved in certain significant markets, such as the United States market.
• The company's inability to fully protect and exploit its intellectual property and trade secrets may adversely affect its financial performance and prospects.
• The dual listing of the company's ordinary shares may adversely affect the liquidity and value of the ordinary shares.
• The company may be adversely affected by general political, unstable market and economic conditions and other events beyond its control.

Future Outlook

The company expects to fund its operations for at least 12 months from the date of the report and expects to obtain marketing authorization in the United States and be commercially available in the first quarter of 2025.

Industry Context

The medical technology industry is highly competitive, subject to change and significantly affected by new product introductions and other activities of industry participants. The company competes as a second line therapy in the OSA treatment market for patients with moderate to severe OSA.

Comparison to Industry Standards

• The company considers other companies that have designed hypoglossal nerve stimulation technologies to treat OSA as direct competitors.
• The company is aware of only one currently marketed nerve stimulation device for the treatment of OSA, the Inspire Medical system marketed by Inspire Medical Systems, Inc.
• The Inspire Medical system is currently the only neuro stimulation system approved to treat moderate to severe OSA in the United States.
• Additionally, the company also considers, as indirect competition, invasive surgical treatment options such as uvulopalatopharyngoplasty and maxillomandibular advancement surgery, and, to a lesser extent, mandibular advancement devices, which are primarily used in the treatment of mild to moderate OSA.

Related Party Transactions

• Robert Taub, who represents Robelga SRL as chairman of our board of directors, had expressed interest in participating in an underwritten public offering, or the May 2024 Offering, of our ordinary shares prior to the launch of the offering.
• The board of directors approved Mr. Taubs participation on May 22, 2024, pursuant to the related parties procedure of Article 7:97 of the Belgian Companies and Associations Code.

Stakeholder Impact

• The company's performance and strategic initiatives will impact shareholders, employees, customers, suppliers, and creditors.

Next Steps

• Continue to develop and commercialize the Genio system.
• Seek marketing authorization for the Genio system in the United States.
• Expand the indications for the Genio system.
• Continue to build a commercial infrastructure in selected geographies.
• Pursue and establish favorable reimbursement coverage of the Genio system.

Key Dates

Keywords

Nyxoah, Genio system, Obstructive Sleep Apnea, OSA, Financial results, Clinical trials, Regulatory approvals, Material weaknesses, Internal control, Financial statements